The authors showed that mutant ESR1 tumors are highly dependent on HSP90, and preclinical studies with the HSP90 inhibitor STA9090 demonstrated cytotoxicity alone and in combination with raloxifene and fulvestrant to ex vivo cultured circulating breast tumor cells [78]. The gene discussed is ESR1; the disease is breast neoplasm.